43 lbs in 16 weeks!! That's amazing results. Congratulations! I'm on the waitlist for a GLP-1 prescription and hearing about results like this makes the wait so hard. How did you get into the clinical trial? Is enrollment still open?

Thanks! I found the trial through ClinicalTrials.gov and was screened at a local research site. I believe most TRIUMPH trial sites have finished enrollment, but you can check ClinicalTrials.gov for any remaining open sites — search for "retatrutide" and filter by recruiting status.

The enrollment process was extensive: multiple screening visits, blood work, ECG, medical history review, and informed consent. It's not as simple as walking in and getting the drug. And of course, there's always the possibility of being randomized to placebo (though I was fortunate to be on active drug).

For context on the rate of weight loss, here's how the OP's trajectory compares to mean trial data:

• OP at 16 weeks: 16.1%
• Phase 2 mean at 24 weeks (12mg): ~17% (estimated from published curves)
• Phase 2 mean at 48 weeks (12mg): 24.2%

The OP is trending above the Phase 2 mean curve, which is not unusual — individual responses vary and the OP's BMI at baseline was relatively high, which often correlates with faster absolute (but not always percentage) weight loss.

The weight loss curve typically follows a logarithmic pattern: steep early, gradually flattening. I'd expect the OP's rate to slow over the next 8-16 weeks as the body adapts and the caloric deficit narrows (lower body weight = lower TDEE).

Appreciate this thread and the responsible way it's being discussed. Reminder that clinical trial participants are bound by their informed consent agreements — please be mindful of what specific details you share publicly, as some trial protocols restrict participant disclosure.

For anyone considering clinical trial participation: it's a legitimate and valuable way to access investigational therapies while contributing to scientific knowledge. But it comes with real obligations (scheduled visits, monitoring, potential placebo assignment) and shouldn't be viewed as a shortcut to getting a drug early.